Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity.

Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S.

Cell Microbiol. 2007 Jul;9(7):1683-94. Epub 2007 Feb 23.

PMID:
17324159
2.

The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.

Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Rückle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O.

Antiviral Res. 2013 Sep;99(3):336-44. doi: 10.1016/j.antiviral.2013.06.008. Epub 2013 Jun 28.

PMID:
23811282
3.

The NF-κB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.

Ehrhardt C, Rückle A, Hrincius ER, Haasbach E, Anhlan D, Ahmann K, Banning C, Reiling SJ, Kühn J, Strobl S, Vitt D, Leban J, Planz O, Ludwig S.

Cell Microbiol. 2013 Jul;15(7):1198-211. doi: 10.1111/cmi.12108. Epub 2013 Feb 5.

PMID:
23320394
4.

A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance.

Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, Planz O, Ludwig S.

Antiviral Res. 2007 Oct;76(1):38-47. Epub 2007 Jun 4.

PMID:
17572513
5.

Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.

Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.

PMID:
21777621
6.

Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy.

Ludwig S.

J Antimicrob Chemother. 2009 Jul;64(1):1-4. doi: 10.1093/jac/dkp161. Epub 2009 May 6. Review.

PMID:
19420020
7.

Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L.

Antimicrob Agents Chemother. 2008 Dec;52(12):4331-7. doi: 10.1128/AAC.00506-08. Epub 2008 Sep 29.

8.

N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.

Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr.

Biochem Pharmacol. 2010 Feb 1;79(3):413-20. doi: 10.1016/j.bcp.2009.08.025. Epub 2009 Sep 2.

PMID:
19732754
9.

Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus.

Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG.

J Gen Virol. 2007 Apr;88(Pt 4):1266-74.

PMID:
17374771
10.

Inhibition of lung serine proteases in mice: a potentially new approach to control influenza infection.

Bahgat MM, Błazejewska P, Schughart K.

Virol J. 2011 Jan 20;8:27. doi: 10.1186/1743-422X-8-27.

11.

Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses.

Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, D'Ostilio D, Vignolo E, Donatelli I, Cassone A.

Virol J. 2007 May 3;4:39.

12.

Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo.

Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S.

Antiviral Res. 2011 Oct;92(1):45-56. doi: 10.1016/j.antiviral.2011.05.009. Epub 2011 May 27.

PMID:
21641936
13.

Infection of human retinal pigment epithelial cells with influenza A viruses.

Michaelis M, Geiler J, Klassert D, Doerr HW, Cinatl J Jr.

Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5419-25. doi: 10.1167/iovs.09-3752. Epub 2009 Jun 24.

PMID:
19553611
14.

Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1.

Zhang T, Wang TC, Zhao PS, Liang M, Gao YW, Yang ST, Qin C, Wang CY, Xia XZ.

Int Immunopharmacol. 2011 Dec;11(12):2057-61. doi: 10.1016/j.intimp.2011.08.019. Epub 2011 Sep 18.

PMID:
21933722
15.

Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.

Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF.

Antivir Chem Chemother. 2012 May 14;22(5):205-15. doi: 10.3851/IMP2080.

PMID:
22374988
16.

Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy.

Ludwig S, Planz O.

Biol Chem. 2008 Oct;389(10):1307-12. doi: 10.1515/BC.2008.148. Review.

PMID:
18713017
17.

Active NF-kappaB signalling is a prerequisite for influenza virus infection.

Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M, Staudt LM, Rosenwald A, Behrends U, Bornkamm GW, Mautner J.

J Gen Virol. 2004 Aug;85(Pt 8):2347-56.

PMID:
15269376
18.

A plant extract of Ribes nigrum folium possesses anti-influenza virus activity in vitro and in vivo by preventing virus entry to host cells.

Ehrhardt C, Dudek SE, Holzberg M, Urban S, Hrincius ER, Haasbach E, Seyer R, Lapuse J, Planz O, Ludwig S.

PLoS One. 2013 May 23;8(5):e63657. doi: 10.1371/journal.pone.0063657. Print 2013.

19.

Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate.

Wiesener N, Zimmer C, Jarasch-Althof N, Wutzler P, Henke A.

Med Microbiol Immunol. 2011 May;200(2):115-26. doi: 10.1007/s00430-010-0182-x. Epub 2010 Dec 21.

PMID:
21174118
20.

Supplemental Content

Support Center